Cell Engineering
We support both autologous and allogeneic cell engineering
Today, cell engineering is one of the most successful applications of advanced medicine. Porton Advanced offers both autologous and allogeneic cell engineering platforms with integrated supports including CRO service, process development, analytical development, cGMP manufacturing, testing services, and regulatory assistance.
Our Services
Thanks to our extensive experience and expertise, we are able to offer a complete, end-to-end service for cell engineering development and manufacturing:
PROCESS DEVELOPMENT FOR cell engineering
Support of over 11 types of cell engineering
Porton Advanced has developed a mature process platform and has accumulated rich CMC experience for different types of cell engineering. At the same time, we continue to invest resources in optimization and development of new process technologies to meet the needs and challenges of industry development.
Process platforms dedicated for different types of cell engineering
Porton Advanced has established numerous types of cell engineering-related processes and platforms. Our team can deliver, with efficiency and high-quality, various types of customized products.
- CAR-T, TCR-T, UCAR-T, etc.
- mesenchymal stem cells (MSC)
- hematopoietic stem cells (HSC)
- Tumor infiltrating lymphocytes (TIL)
- NK/NK92/CAR-NK
- Closed system for PBMC apheresis from healthy/patient donor
- Manufacturing process for fresh and freezing PBMC
- Raw Material selection (including china vendor replacement)
- Multiple viral vector transduction processes and optimal solution selection
- Closed electrophoresis system for gene editing (including china vendor replacement)
- Closed expansion system of XuriWAVE, G-Rex, and culture bag
- Closed system for cell harvest and purification (including large-scale manufacturing)
- Formulation, cryopreservation, and fill–finish for frozen drug products
- Independent cell engineering suites for donors with infectious disease
- MSC separation processes from different tissue source (including fat, umbilical cord, placental tissue, bone marrow tissue, etc.)
- Autologous and allogeneic cell engineering processes
- Material selection (including China vendor replacement)
- Lentiviral vector transduction process (optional)
- Expansion process in cell factory/ super cell factory
- cGMP cell banking process
- Closed system for cell harvest and purification (including largescale manufacturing)
- Formulation, cryopreservation, and fill–finish for frozen drug product
- Closed separation process for mobilized leukapheresis HSC Material selection (including china vendor replacement)
Stimulation process for HSC - Lentiviral vector transduction process (optional)
- Closed system for cell harvest and purification (including largescale manufacturing)
- Independent cell engineering suites for donors with infectious disease
- TIL separation process from different tumor sources
- Material selection (including china vendor replacement)
- Feeder cell preparation process
- Irradiation process (including china vendor replacement)
- Lentiviral vector transduction process (optional)
- Closed and rapid TIL expansion process in GRex or XuriWAVE
- Closed system for cell harvest and purification (including largescale manufacturing)
- Formulation, cryopreservation, and fill–finish for frozen drug products
- Independent cell engineering suites for donors with infectious disease
- NK culture process from different sources (PBMC, CBMC, etc.)
- Material selection (including china vendor replacement)
- Separation process for NK cells
Multiple activation processes for NK cells - Feeder and feederfree expansion process
- Multiple NK transduction processes (including lentivirus, γretrovirus, electrophoresis)
- Serumfree culture process for NK cells
- Closed perfusion culture technologies for NK/CARNK cells
- Closed cell harvest and purification process for NK/CARNK cells (including largescale manufacturing)
- Formulation, cryopreservation, and fill–finish for frozen drug products
- Autologous and allogeneic manufacturing processes
Process platforms for multiple cell engineering types
- Viral vector transduction
- Non-viral vector electroporation (plasmid, mRNA, RNP, etc.)
- Irradiation (K562, PBMC, etc.)
For CAR-T or TCR-T, lentiviral static transduction is usually used without the addition of transduction enhancers. The VCN (Vector Copy Number) of healthy CD3-positive cells is controlled to be no more than 3, and CAR or TCR positive rate is 60~90%.
According to various client request, Porton Advanced designs and explores optimal electroporation proecess for efficiently knock-in/out target genes by numerous electroporation equipment (including Lonza, Thermo, Etta and so on).
To reach specification of cell engineering excipients, Porton Advanced can perform irradiation on feeder cells by our own irradiation equipment.
CGMP cell engineering MANUFACTURING
Supporting from pre-IND to clinical trials
Porton Advanced has successfully obtained clinical approval for 8 IND applications since the launch of our first cell engineering cGMP production line back in 2020. We now provide CDMO services for dozens of cell engineering projects at varying stages such as investigator-initiated trials, preclinical trials, IND applications, clinical trials, and more. So far, Porton Advanced has 12 independent production lines, which allows us to simultaneously produce autologous cell products, allogeneic cell engineering products, and cell engineering products with more closed operations.
CELL BANKING SERVICE
12 closed system cell engineering cGMP production lines
Cell banking workflow
CELL BANKING SERVICE
Qualified for IND/BLA application in China and US
Porton Advanced provides three-tiered cell banking services (cell lines including MSC, k562, etc.) based on adhesion and suspension processes. Our technical team will establish a three-tiered cell bank in a cGMP environment and perform programmed cooling and cryopreservation to maximize cell viability.